Alterity Therapeutics Ltd ADR (ATHE) Stock Price, Quote & News

Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9349 4906

Fax: 61 3 9349 4906

Website: alteritytherapeutics.com

Address:

350 Collins Street, Suite 4 Level 14, Melbourne, Australia

theaussiebloke Oct. 3 at 10:07 AM

$ATHE low vol here on the ASX today, i feel the ATHE will remain at current range.

1 · Reply

HouseOfTheDragons Oct. 3 at 2:33 AM

Looks like volume & momentum could be shifting in to ASTC! Tiny float getting a lot of attention and could explode upwards on volume. Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Also watching for breakout: $ARBB $ASST $ATHE $AVTX ---

0 · Reply

stckmuncher Oct. 3 at 2:28 AM

$ATHE Shorts clinching their buttholes a little bit today…

0 · Reply

RocketMan88 Oct. 2 at 10:16 PM

$ATHE when this blows up and we are all worth $20M+ are we gonna have an ATHE meet up in Vegas?

1 · Reply

DARKP00L Oct. 2 at 11:53 AM

$ATHE 07:37 on Oct. 02 2025 Alterity to Present Multiple System Atrophy Drug Trial Results at Major Parkinson's Conference in Hawaii #tradeideas

0 · Reply

MrTicker Oct. 2 at 11:37 AM

$ATHE Alterity to Present Multiple System Atrophy Drug Trial Results at Major Parkinson's Conference in Hawaii BENZINGA 6:37 AM ET 10/2/2025

0 · Reply

TwongStocks Oct. 2 at 11:36 AM

$ATHE Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders https://alteritytherapeutics.com/investor-centre/news/2025/10/02/alterity-therapeutics-to-deliver-multiple-presentations-at-the-2025-international-congress-of-parkinsons-disease-and-movement-disorders/ Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations

0 · Reply

RobGro Oct. 2 at 11:33 AM

$ATHE When we get to 9000 watchers this things gunna fly 🚀

1 · Reply

Double__Down Oct. 2 at 1:35 AM

$ATHE does this seem like new information being presented? Or same script, different conference? https://alteritytherapeutics.com/investor-centre/news/2025/10/02/alterity-therapeutics-to-deliver-multiple-presentations-at-the-2025-international-congress-of-parkinsons-disease-and-movement-disorders/

2 · Reply

RocketMan88 Oct. 1 at 3:10 PM

$ATHE @stckmuncher have you run into the CEO lately? Need an update.

2 · Reply

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Sep 8, 2025, 7:35 AM EDT - 26 days ago

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

Sep 2, 2025, 7:25 AM EDT - 4 weeks ago

Alterity Therapeutics to Present at the Biotech Showcase

Jul 30, 2025, 7:25 AM EDT - 2 months ago

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Jul 28, 2025, 7:25 AM EDT - 2 months ago

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

Jul 24, 2025, 7:25 AM EDT - 2 months ago

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

Jun 23, 2025, 7:25 AM EDT - 3 months ago

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

May 12, 2025, 7:35 AM EDT - 5 months ago

Alterity Therapeutics Prominently Featured at the International MSA Congress

May 7, 2025, 8:16 AM EDT - 5 months ago

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

May 5, 2025, 7:35 AM EDT - 5 months ago

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Apr 30, 2025, 7:35 AM EDT - 5 months ago

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Apr 28, 2025, 7:35 AM EDT - 5 months ago

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Apr 10, 2025, 7:35 AM EDT - 6 months ago

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Mar 27, 2025, 7:25 AM EDT - 6 months ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Feb 10, 2025, 7:25 AM EST - 8 months ago

Alterity Therapeutics Raises A$40.0 million in Placement

Jan 30, 2025, 7:35 AM EST - 8 months ago

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Jan 24, 2025, 7:35 AM EST - 9 months ago

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Jan 9, 2025, 7:25 AM EST - 9 months ago

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Dec 4, 2024, 7:35 AM EST - 10 months ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Nov 19, 2024, 7:25 AM EST - 11 months ago

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Nov 12, 2024, 7:35 AM EST - 11 months ago

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Nov 6, 2024, 7:35 AM EST - 11 months ago

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Oct 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Oct 14, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Oct 11, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Oct 2, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Sep 30, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Sep 23, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Jul 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Jul 24, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Present at MST Financial Webinar

Jul 17, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jul 17, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jun 12, 2024, 7:22 PM EDT - 1 year ago

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

May 29, 2024, 7:21 PM EDT - 1 year ago

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

May 8, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Apr 30, 2024, 7:25 AM EDT - 1 year ago

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Apr 29, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

Apr 17, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Apr 10, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

Mar 26, 2024, 10:25 AM EDT - 1 year ago

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

Feb 20, 2024, 10:25 AM EST - 1 year ago

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

Feb 6, 2024, 7:25 AM EST - 1 year ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Jan 29, 2024, 7:24 AM EST - 1 year ago

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

Dec 21, 2023, 12:30 AM EST - 1 year ago

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

Dec 4, 2023, 4:35 PM EST - 1 year ago

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

Dec 4, 2023, 7:25 AM EST - 1 year ago

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

Nov 27, 2023, 7:25 AM EST - 2 years ago

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Nov 16, 2023, 7:25 AM EST - 2 years ago

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

Nov 8, 2023, 7:25 AM EST - 2 years ago

Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy

Oct 30, 2023, 7:25 AM EDT - 2 years ago

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

theaussiebloke Oct. 3 at 10:07 AM

$ATHE low vol here on the ASX today, i feel the ATHE will remain at current range.

1 · Reply

HouseOfTheDragons Oct. 3 at 2:33 AM

0 · Reply

stckmuncher Oct. 3 at 2:28 AM

$ATHE Shorts clinching their buttholes a little bit today…

0 · Reply

RocketMan88 Oct. 2 at 10:16 PM

$ATHE when this blows up and we are all worth $20M+ are we gonna have an ATHE meet up in Vegas?

1 · Reply

DARKP00L Oct. 2 at 11:53 AM

$ATHE 07:37 on Oct. 02 2025 Alterity to Present Multiple System Atrophy Drug Trial Results at Major Parkinson's Conference in Hawaii #tradeideas

0 · Reply

MrTicker Oct. 2 at 11:37 AM

$ATHE Alterity to Present Multiple System Atrophy Drug Trial Results at Major Parkinson's Conference in Hawaii BENZINGA 6:37 AM ET 10/2/2025

0 · Reply

TwongStocks Oct. 2 at 11:36 AM

0 · Reply

RobGro Oct. 2 at 11:33 AM

$ATHE When we get to 9000 watchers this things gunna fly 🚀

1 · Reply

Double__Down Oct. 2 at 1:35 AM

2 · Reply

RocketMan88 Oct. 1 at 3:10 PM

$ATHE @stckmuncher have you run into the CEO lately? Need an update.

2 · Reply

theaussiebloke Oct. 1 at 12:00 PM

$ATHE whats americas plans for today, push this down further ? idle for a few days, start looking back up ?

1 · Reply

tommy_john Sep. 29 at 10:32 AM

$ATHE unfortunately they killed momentum with dilution. Another 3 million shares. And a gap at $3.44. That is the next buy area imo

2 · Reply

BrokersNY Sep. 29 at 8:35 AM

$ATHE not long from now on, when its commercialised this thing will be 3 digits

1 · Reply

AshleySchaeffer_BMW Sep. 29 at 3:45 AM

$ATHE news!!! From down under

0 · Reply

anastasia_beaverhausen1 Sep. 29 at 2:41 AM

$ATHE

0 · Reply

Happy1991 Sep. 28 at 7:09 PM

$ATHE start falling be .50 cents and then reverse split

0 · Reply

stckmuncher Sep. 27 at 12:02 AM

$ATHE My buddies Scottie and Alexia were just hanging out with the CFO in Guam, big things to come baby!!!!

1 · Reply

Botmax Sep. 26 at 9:15 AM

$ATHE well those still sitting on the sidelines looking for a good time to average in. Well ..

0 · Reply

stckmuncher Sep. 25 at 10:55 PM

$ATHE Someone please fluff me because I am losing faith.

0 · Reply

RocketMan88 Sep. 25 at 10:55 PM

$ATHE had a shopping spree and loaded up on shares today. When the market has a Black Friday sale you load up you don’t run away. Trade with data and logic not emotion.

1 · Reply

stckmuncher Sep. 25 at 10:54 PM

$ATHE Are we all fucked!?

1 · Reply

motherlandreturns Sep. 25 at 8:14 PM

$ATHE so why is this averaging further below 5?

0 · Reply

Market Cap	37.15M
Revenue (ttm)	0.00
Net Income (ttm)	-7.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	10,300
Avg Vol	71,398
Day's Range	N/A - N/A
Shares Out	8.87M
Stochastic %K	67%
Beta	0.30
Analysts	Strong Sell
Price Target	$11.00